HYMOVIS
Fidia Farmaceutici SpA
Application Filed: 2009-12-18
Trademark Application Details
PARTIAL SECTION 8 ACCEPTED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 77896635 |
| Registration Number | 4148241 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Cancellation Code | B |
| Domestic Representative | Fross Zelnick Lehrman & Zissu, P.C. |
| Attorney Name | Andrew N. Fredbeck |
| Attorney Docket Number | FIQ 0908028 |
| Law Office Assigned | L90 |
| Employee Name | ROSSMAN, MARY JO |
Timeline
| 2009-12-18 | Application Filed |
| 2012-03-13 | Published for Opposition |
| 2012-05-29 | Trademark Registered |
| 2018-05-25 | Location: |
| 2018-05-25 | Status: Live/Registered |
| 2018-07-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Fidia Farmaceutici SpA |
| Address | Via Ponte Della Fabbrica 3/A I-35031 Abano Term IT |
| Legal Entity Type | Joint Stock Company |
| Legal Entity State | IT |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 10 |
| U.S. Codes: | 026,039,044 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations for the prevention and treatment of joint diseases and articular disorders, of traumatic and degenerative joint pathologies and for use during orthopedic surgery; [ veterinary preparations for the treatment of joint diseases and articular disorders of animals; ] prepacked injectable solutions for the prevention and treatment of joint diseases and articular disorders, of traumatic and degenerative joint pathologies and for use during orthopedic surgery |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2009-12-22 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2009-12-24 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2010-03-19 | 3 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2010-03-25 | 4 CNRT R:Renewal |
| NON-FINAL ACTION MAILED | 2010-03-26 | 5 CNRT F:First Action |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2010-09-24 | 6 TROA I:Incoming Correspondence |
| ASSIGNED TO LIE | 2010-09-30 | 7 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2010-09-30 | 8 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2010-09-30 | 9 TEME I:Incoming Correspondence |
| SUSPENSION LETTER WRITTEN | 2010-10-29 | 10 CNSL R:Renewal |
| LETTER OF SUSPENSION MAILED | 2010-11-01 | 11 CNSL S: |
| LIE CHECKED SUSP - TO ATTY FOR ACTION | 2011-05-04 | 12 RCCK S: |
| SUSPENSION INQUIRY WRITTEN | 2011-06-14 | 13 CNSI R:Renewal |
| INQUIRY AS TO SUSPENSION MAILED | 2011-06-14 | 14 CNSI S: |
| TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | 2011-06-24 | 15 ERSI I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2011-07-06 | 16 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2011-07-06 | 17 TEME I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2011-07-29 | 18 CNFR R:Renewal |
| FINAL REFUSAL MAILED | 2011-08-01 | 19 CNFR O:Outgoing Correspondence |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2012-01-20 | 20 ERFR I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2012-01-20 | 21 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2012-01-21 | 22 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2012-02-06 | 23 CNSA O:Outgoing Correspondence |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2012-02-07 | 24 PREV O:Outgoing Correspondence |
| NOTICE OF PUBLICATION | 2012-02-22 | 25 NPUB O:Outgoing Correspondence |
| PUBLISHED FOR OPPOSITION | 2012-03-13 | 26 PUBO A:Allowance for Publication |
| REGISTERED-PRINCIPAL REGISTER | 2012-05-29 | 27 R.PR A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2017-01-31 | 28 CRFA I:Incoming Correspondence |
| REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED | 2017-04-05 | 29 CORV 1: |
| TEAS SECTION 8 RECEIVED | 2018-05-23 | 30 ES8R I:Incoming Correspondence |
| CASE ASSIGNED TO POST REGISTRATION PARALEGAL | 2018-05-24 | 31 APRE A:Allowance for Publication |
| REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED | 2018-05-25 | 32 8.PR O:Outgoing Correspondence |
| NOTICE OF ACCEPTANCE OF SEC. 8 - MAILED | 2018-05-25 | 33 NAS8 O:Outgoing Correspondence |
| TEAS SECTION 8 & 9 RECEIVED | 2022-05-27 | 34 E89R I:Incoming Correspondence |
| REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | 2022-06-07 | 35 89AG O:Outgoing Correspondence |
| REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | 2022-06-07 | 36 RNL1 Q: |
| NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | 2022-06-07 | 37 NA89 E:E-Mail |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 HYMOVIS 79171133 4929840 Live/Registered |
FIDIA FARMACEUTICI S.p.A. 2015-04-20 |
 HYMOVIS 77896635 4148241 Live/Registered |
Fidia Farmaceutici SpA 2009-12-18 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 